Last reviewed · How we verify
NCT06259279: HIP
High Impact Training to Patients with Prostate Cancer and Bone Metastases
NA trial testing High intensity high impact exercise intervention in Prostate Cancer in 102 participants. Currently enrolling.
31 December 2026
Quick facts
| Lead sponsor | Copenhagen University Hospital at Herlev |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | supportive care |
| Enrollment | 102 |
| Start date | 6 February 2024 |
| Primary completion | 31 December 2026 |
| Estimated completion | 31 December 2026 |
| Sites | 1 location across Denmark |
Drugs / interventions tested
- High intensity high impact exercise intervention
Conditions studied
- Prostate Cancer — all drugs for Prostate Cancer →
Sponsor
Copenhagen University Hospital at Herlev
Who can join
18 and older, male only, with Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
HIP is a randomized controlled trial. The aim is investigate the effect, safety and feasibility of brief, high-impact exercise targeting bones in patients with prostate cancer and bone metastases. Furthermore, to investigate the effects of the intervention on bone status (bone mineral density) and body composition, physical function and performance, patient reported quality-of-life outcomes, falls and hospitalizations. The effects of resistance training on the antitumor immunity will be assessed in the peripheral blood and tumor biopsies (HIPimmune).
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
High-intensity resistance and impact training for patients with hormone-sensitive prostate cancer and bone metastases-study protocol of a randomized clinical trial.
Ragle AM, Mikkelsen MK, Vinther A, Zerahn B, et al · · 2025 · PMID 40722114 · DOI 10.1186/s13063-025-08937-0
Verify or expand the search:
- PubMed search for NCT06259279
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Prostate Cancer
Currently open trials in the same condition.
- NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
- NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
- NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
- NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
- NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting
Other Copenhagen University Hospital at Herlev trials
Trials by the same sponsor.
- NCT06802991 — Optimised Post-discharge Care in Older Patients After Surgery for Colon Cancer (ERAS 3.0) · NA · recruiting
- NCT06440616 — Benefit of Spectral Information in Patients Suspected for Lung Cancer · NA · recruiting
- NCT06234306 — Molecularly Redefining Small Bowel Adenocarcinoma to Accelerate Precision Patient Care · recruiting
- NCT06089551 — Early vs Postponed Parenteral Nutrition After Emergency Abdominal Surgery · Phase 4 · unknown
- NCT05736237 — Identification and Verification of Candidate Genes Responsible for Optic Disc Drusen Development · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06259279 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Copenhagen University Hospital at Herlev
- Last refreshed: 13 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06259279.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing